Recent Updates
Recently added Catalysts
GLPG

Galapagos receives transparency notification from Wellington Management Group LLP

Key Takeaway: Mechelen, Belgium; 25 October 2019; 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from Wellington Management Group LLP. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notificat

Full Press Release Details

Mechelen, Belgium; 25 October 2019; 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from Wellington Management Group LLP.
Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 22 October 2019 from Wellington Management Group LLP, who indicated that, following a disposal of ordinary shares, the remaining 3,079,573 Galapagos ordinary shares held by its entirely-controlled subsidiary Wellington Management Company LLP represent 4.97% of the current 61,953,831 outstanding Galapagos shares and thus, with the ordinary shares portion of its total position, crossed below the 5% threshold of Galapagos’ voting rights on 8 October 2019. In addition, through its wholly owned subsidiary Wellington Management Company LLP, it now also holds 615,676 American Depositary Shares and 8,322 equity swaps with expiration in 2020, bringing the new total number of voting rights for Wellington Management Group to 3,703,571, which represents 5.98% of total outstanding shares. The full transparency notice is available on the Galapagos website.
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. The company’s pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Galapagos’ ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
Investors:                                                          Media:
Elizabeth Goodwin                                                Carmen Vroonen
VP IR                                                                   Senior Director Communications
+1 781 460 1784                                                  +32 473 824 874
Sofie Van Gijsel                                                     Evelyn Fox
Director IR                                                            Director Communications
+32 485 19 14 15                                                +31 6 53 591 999
ir@glpg.com                                                communications@glpg.com
1    Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market

Attachments

Last updated: Oct 25, 2019